Kang Yongbo, Cai Yue
Medical School, Kunming University of Science and Technology, Kunming 650500, Yunnan, China; Genetics and Pharmacogenomics Laboratory, Kunming University of Science and Technology, Kunming 650500, Yunnan, China.
Medical School, Kunming University of Science and Technology, Kunming 650500, Yunnan, China; Pathogen biology Laboratory, Kunming University of Science and Technology, Kunming 650500, Yunnan, China.
Clin Res Hepatol Gastroenterol. 2018 Apr;42(2):110-117. doi: 10.1016/j.clinre.2017.09.006. Epub 2017 Nov 1.
Hypertension (HTN) has become a global public health concern and a major risk factor for cardiovascular, cerebrovascular, and kidney diseases. The complex interplay of genetic and environmental influences is important for the development of the disease. Accumulating evidence has illustrated the association of dysbiosis of gut microbiota with hypertension. Certain gut microbial strains may play either a pathogenic or a protective role in the development of hypertension. Oral probiotics can therefore represent a therapeutic approach for hypertension treatment. However, the relevant scientific work has only just begun, and the available data in this field remain limited. Fortunately, recent technological developments that permit identification of microbes and their products using culture-independent molecular detection techniques. In this review, we summarize the role of gut microbiota in hypertension progression, and probiotics in the treatment of hypertension.
高血压已成为全球公共卫生问题,是心血管、脑血管和肾脏疾病的主要危险因素。遗传和环境影响的复杂相互作用对该疾病的发展至关重要。越来越多的证据表明肠道微生物群失调与高血压有关。某些肠道微生物菌株可能在高血压的发展中起致病或保护作用。因此,口服益生菌可能是一种治疗高血压的方法。然而,相关的科学工作才刚刚开始,该领域的现有数据仍然有限。幸运的是,最近的技术发展使得使用非培养分子检测技术鉴定微生物及其产物成为可能。在这篇综述中,我们总结了肠道微生物群在高血压进展中的作用以及益生菌在高血压治疗中的作用。